Vogt-Koyanagi-Harada-like Syndrome Complicating Pembrolizumab Treatment for Metastatic Melanoma

Abstract : Vogt-Koyanagi-Harada (VKH) syndrome is a rare condition implicating systemic immune reaction against melanocytes. The pathophysiology is unclear. A genetic predisposition has been suggested as HLA-DR4/DRB1*04 is more common among VKH patients. Drug induced VKH syndrome has been reported in advanced melanoma patients receiving immunotherapy, including ipilimumab and adoptive cell transfer of Tumor-Infiltrating Lymphocyte associated with IL-2. To date, no case of anti PD-1 -induced VKH syndrome has been described. We report here the case of a HLA-DR4/DRB1*04 patient successfully treated with anti PD-1 for advanced melanoma who developed a systemic immune reaction against melanocytes for whom we discuss a VKH-like syndrome diagnosis in a potentially genetically predisposed patient
Document type :
Journal articles
Complete list of metadatas

https://hal-univ-lyon1.archives-ouvertes.fr/hal-01795713
Contributor : Lauriane Pillet <>
Submitted on : Friday, May 18, 2018 - 4:38:54 PM
Last modification on : Wednesday, September 26, 2018 - 4:02:02 PM

Identifiers

Collections

Citation

M. Bricout, A. Petre, M. Amini-Adle, W. Bezza, Pascal Seve, et al.. Vogt-Koyanagi-Harada-like Syndrome Complicating Pembrolizumab Treatment for Metastatic Melanoma. Journal of Immunotherapy, Lippincott, Williams & Wilkins, 2017, 40 (1537-4513 (Electronic)), pp.77-82. ⟨10.1097/CJI.0000000000000154⟩. ⟨hal-01795713⟩

Share

Metrics

Record views

17